124 related articles for article (PubMed ID: 22739991)
1. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study.
Arkema EV; van Vollenhoven RF; Askling J;
Ann Rheum Dis; 2012 Nov; 71(11):1865-7. PubMed ID: 22739991
[TBL] [Abstract][Full Text] [Related]
2. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.
Fleischmann RM
Arthritis Rheum; 2009 Nov; 60(11):3225-8. PubMed ID: 19877057
[TBL] [Abstract][Full Text] [Related]
3. Incidence of progressive multifocal leukoencephalopathy in patients without HIV.
Amend KL; Turnbull B; Foskett N; Napalkov P; Kurth T; Seeger J
Neurology; 2010 Oct; 75(15):1326-32. PubMed ID: 20938025
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases.
Molloy ES; Calabrese LH
Arthritis Rheum; 2009 Dec; 60(12):3761-5. PubMed ID: 19950261
[TBL] [Abstract][Full Text] [Related]
5. Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration.
Eriksson JK; Neovius M; Ernestam S; Lindblad S; Simard JF; Askling J
Arthritis Care Res (Hoboken); 2013 Jun; 65(6):870-8. PubMed ID: 23281173
[TBL] [Abstract][Full Text] [Related]
6. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P; Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
[TBL] [Abstract][Full Text] [Related]
7. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
8. Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis.
Borie D; Kremer JM
Semin Arthritis Rheum; 2015 Oct; 45(2):163-6. PubMed ID: 26190565
[TBL] [Abstract][Full Text] [Related]
9. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
Khanna N; Elzi L; Mueller NJ; Garzoni C; Cavassini M; Fux CA; Vernazza P; Bernasconi E; Battegay M; Hirsch HH;
Clin Infect Dis; 2009 May; 48(10):1459-66. PubMed ID: 19348592
[TBL] [Abstract][Full Text] [Related]
10. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
[TBL] [Abstract][Full Text] [Related]
11. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
12. Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?
Eriksson JK; Johansson K; Askling J; Neovius M
Ann Rheum Dis; 2015 Apr; 74(4):648-54. PubMed ID: 24323395
[TBL] [Abstract][Full Text] [Related]
13. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.
Molloy ES; Calabrese LH
Arthritis Rheum; 2012 Sep; 64(9):3043-51. PubMed ID: 22422012
[TBL] [Abstract][Full Text] [Related]
14. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy in autoimmune diseases.
Palazzo E; Yahia SA
Joint Bone Spine; 2012 Jul; 79(4):351-5. PubMed ID: 22281228
[TBL] [Abstract][Full Text] [Related]
18. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.
Ljung L; Simard JF; Jacobsson L; Rantapää-Dahlqvist S; Askling J;
Arthritis Rheum; 2012 Jan; 64(1):42-52. PubMed ID: 21898355
[TBL] [Abstract][Full Text] [Related]
19. Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis.
Hellgren K; Smedby KE; Feltelius N; Baecklund E; Askling J
Arthritis Rheum; 2010 May; 62(5):1252-8. PubMed ID: 20155827
[TBL] [Abstract][Full Text] [Related]
20. The widening mortality gap between rheumatoid arthritis patients and the general population.
Gonzalez A; Maradit Kremers H; Crowson CS; Nicola PJ; Davis JM; Therneau TM; Roger VL; Gabriel SE
Arthritis Rheum; 2007 Nov; 56(11):3583-7. PubMed ID: 17968923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
